ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.99
-0.23 (-2.25%)
At close: Jan 30, 2026, 4:00 PM EST
9.99
0.00 (0.00%)
After-hours: Jan 30, 2026, 5:25 PM EST
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $32.50M in the quarter ending September 30, 2025, with 1,471.62% growth. This brings the company's revenue in the last twelve months to $142.77M, up 5,459.66% year-over-year. In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth.
Revenue (ttm)
$142.77M
Revenue Growth
+5,459.66%
P/S Ratio
7.03
Revenue / Employee
$854,922
Employees
167
Market Cap
987.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | 17.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Iovance Biotherapeutics | 250.43M |
| CytomX Therapeutics | 113.63M |
| Theravance Biopharma | 80.33M |
| Nanobiotix | 11.93M |
| Aktis Oncology | 5.56M |
SPRY News
- 9 days ago - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use - GlobeNewsWire
- 21 days ago - Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Benzinga
- 4 weeks ago - neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) - GlobeNewsWire
- 3 months ago - ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) - GlobeNewsWire